What We're Reading: Page 92
Industry reads hand-picked by our editors
Apr 07, 2023
-
Triangle Business Journal
Robert Ingram, pharma leader who led formation of GSK, dies
-
Financial Times
South Korean biotech companies seek to diversify from China as US tensions rise
-
Stat News
Genentech review of Tessier-Lavigne paper finds no fraud
Apr 06, 2023
-
The Wall Street Journal
These Drugs Are So Futuristic That Doctors Need New Training
-
Fierce Pharma
AZ wins royalties case against GSK over PARP inhibitor Zejula
-
MedTech Dive
Grassroots innovation: How a patient-driven device for diabetes won FDA clearance
Apr 05, 2023
-
Financial Times
New Bayer chief says all options on table after investors push for break-up
-
Fierce Pharma
FDA authorizes InflaRx’s anti-inflammation drug for severe COVID
-
The Wall Street Journal
Farallon Capital to Wage Proxy Battle at Biotech Firm
-
Bloomberg
India’s Drug Industry Needs a Major Overhaul
Apr 04, 2023
-
The Wall Street Journal
Mounjaro Could Eclipse Ozempic as the Most Powerful Weight-Loss Drug
-
Reuters
Arbutus files patent infringement lawsuit against Pfizer/BioNTech over COVID shots
-
Fierce Biotech
Gossamer halts work on BTK inhibitor after 2 patient deaths
-
Bloomberg
Adderall, Xanax Are Hard to Get Because of the Opioid Crisis
Apr 03, 2023
Mar 31, 2023
Mar 30, 2023
-
Science
Promising Alzheimer’s therapy and related drugs shrink brains
-
Politico
Lawmakers press FDA on clinical trial holds
-
The New York Times
AstraZeneca’s Covid Vaccine May Have Posed a Higher Heart Risk for Young Women, Study Shows
-
Bloomberg Law
Biogen Dodges Investor Suit on Failed Alzheimer’s Drug Rollout
Previous
